Adverse reaction after tetrathiomolybdate treatment for Wilson's disease: A case report

✍ Scribed by Valentina Medici; Carlo Pietro Trevisan; Maria Assunta Bigotto; Renata D'Incà; Diego Martines; Elisabetta Dal Pont; Giacomo Carlo Sturniolo

• Publisher: John Wiley and Sons
• Year: 2006
• Tongue: English
• Weight: 65 KB
• Volume: 21
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/mds.21109

✦ Synopsis

muscle: 36.6 U; mean total dosage per session: 282.2 U). In 83.8% of these patients, we injected more than 4 muscles, with a mean of 8.5 treated muscles (mean dosages per kg body weight: 17.9 U; range: 5.1-32.3 U; mean dosage per muscle: 35.6 U; mean total dosage per session: 303.0 U). The data are summarized in Table 1.

We did not observe any cases of adverse events that would have required discontinuation of BoNT therapy. The total rate of adverse events seen here was 8.8%. This is well below the 28% reported by Jankovic and Schwartz 5 for the treatment of cervical dystonia in adult patients (58 of 205 patients). Thus, over a 5-year observational period, BoNT (preparation Botox) proved safe and effective in our multimuscle treatment regimen. 6 These clinical observations are supported by experiments in a mouse model showing that BoNT (preparation Botox) has a migration profile with a particularly broad safety margin. 7 In conclusion, as far as pharmacotherapy with BoNT is concerned, some of the needs of children with CP can be met: we can safely treat more muscles and give more substance.